-
-
-
-
-
-
-
Cogent Biosciences reports 65% response rate in mastocytosis trial
-
-
-
-
-
-
-
Jefferies says these are the best SMID-cap biotech stocks to buy
-
-
-
-
-
-
-
Raymond James Reiterates Strong Buy Rating on Cogent (COGT)
-
-
-
-
-
-
-
Cogent Biosciences submits drug application for systemic mastocytosis
-
-
-
-
-
-
-
Increasing unusual call option volume: BRR COGT JANX MDB EH KMB TSEM UNFI SIG FRPT TXG
-
-
-
-
-
-
-
Cogent Biosciences presents KRAS inhibitor data at cancer conference
-
-
-
-
-
-
-
Cogent Biosciences (COGT) spreader of November 13 and 20 calls
-
479,029 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All


